Did FDA-App Recalls and Activist Pressure Just Rewire Dexcom’s (DXCM) Software-Driven Investment Narrative?
Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
Citigroup Maintains Buy on DexCom, Raises Price Target to $84
Signos raises $20M, expands Dexcom partnership for weight loss
Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users
DexCom Reveals Stolen Lots Of Scrapped Dexcom G7 Sensors Were Sold And Used By Customers, Launches Investigation With FDA And Authorities To Protect Patient Safety
DexCom Flex Launch Targets Wider Type 2 Market With Valuation Upside
Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years
Harnessing medtech market alliances, ŌURA sets IPO plans in motion
Analysts Upgrade DexCom (DXCM) to “Outperform,” Driving Share Recovery
DexCom Might Finally Be Cheap Enough
The DexCom Stock Turnaround Is Showing Real Signs of Life
DXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in Germany
14. OURA
Canaccord Genuity Maintains Buy on DexCom, Lowers Price Target to $82
B of A Securities Maintains Buy on DexCom, Lowers Price Target to $80
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany
Barclays Maintains Underweight on DexCom, Lowers Price Target to $64
DexCom Rolls Out Glucose Monitoring System Dexcom Flex In Germany
DexCom, Inc. (DXCM) Analyst/Investor Day - Slideshow
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.